Metastatic renal cancer is one of the models used for immunotherapy study. Interleukin-2 is active in this chemo and radioresistant tumour and induces the regression of diffuse metastatic lesions sometimes completely through the activation of the immune system. Interleukin-2 has also led to the development of new therapeutic approaches in oncology such as TIL and gene transfer.